Oragenics, Inc. Announces Pricing of Public Offering

The gross proceeds of the offering are anticipated to be approximately $1,100,000 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, fil ...